An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a recent study. Read the article.
Experimental urine test identifies 92% of men with elevated PSA levels Read More »
A study compared diagnostic outcomes between 2 different techniques for targeting regions-of-interest on prostate multiparametric Magnetic resonance imaging (mpMRI); MRI-ultrasound fusion (MR-F) and visually targeted (VT) biopsy. No evidence was found of a significant difference in the detection of high-grade or any-grade cancer between VT and MR-F biopsy. However, the performance of each technique varied in specific biopsy locations, and the outcomes of both techniques were complementary. Combining VT biopsy and MR-F biopsy may optimize prostate cancer detection. Read the article.
In a study of 8,820 men with metastatic castration-resistant prostate cancer, researchers found the prognosis differs substantially based on where the cancer has spread. Spread to the liver is associated with shorter survival than lung and bone spread, and patients with lymph node metastases only have the best overall survival. Read the article.
Prostate Ca: Site of metastases impacts prognosis Read More »
The new Memorial Sloan Kettering Cancer Center’s recommendations for prostate cancer screening provide a model for prostate cancer screening that maximizes the benefits, in terms of reduction in prostate cancer-specific mortality, and minimizes harms to men from overdiagnosis and overtreatment. Read the article.
A new study is suggesting that a blood test for examining sex hormone levels can predict how aggressive prostate cancer is in a patient. Read the article.
Blood Tests Can Predict How Aggressive Prostate Cancer Is, Study Says Read More »
In a small study of men with prostate cancer, researchers found a novel agent combined with positron emission tomography (PET) imaging detected 97% of cancerous lesions. Read the article.
PCa agent detects 97% of lesions when paired with PET Read More »
Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today. Read the article.
New imaging test detects prostate cancer much better than any other tests in use today Read More »
A recent study out of Johns Hopkins shows that a new and simple grading system may be effective for predicting outcomes in men with prostate cancer. In fact, the researchers say the test — in an analysis of 20,000 men — appears to be an improvement over the Gleason grading system, the current standard. Read the article.
New Prostate Cancer Grading System Found Superior to Gleason System Read More »
MRF-TB (magnetic resonance imaging-ultrasound fusion targeted prostate biopsy) may improve the detection of prostate cancer in men presenting for prostate biopsy. In men presenting for primary prostate biopsy MRF-TB detects more high grade cancers than systematic biopsy. Most cancers detected by systematic biopsy and not by MRF-TB are at clinically low risk. Prebiopsy magnetic resonance imaging followed by MRF-TB decreases the detection of low risk cancers while significantly improving the detection and risk stratification of high grade disease. Read the article.
MRI-Ultrasound Fusion Biopsy Detects High-Grade Prostate Cancer Read More »
Dr. Eleftherios Diamandis, a researcher at Toronto’s Mount Sinai Hospital, would like a better alternative that could reduce unnecessary biopsies. Dr. Diamandis plans to spend the next two years developing a non-invasive test that can help determine when high PSA levels warrant concern. To do this, he will zero in on genetic mutations found in the semen of men with prostate cancer and use those biomarkers to screen other men for the disease. Read the article.
Semen-based test for diagnosing prostate cancer could reduce unnecessary biopsies Read More »